Kadima, Israel

Ohad Ilovich

This inventor holds 1 USPTO granted patent. Top assignee: Hadasit Medical Research Services and Development Ltd.. Active years: 2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ohad Ilovich. Retrieved from https://idiyas.com/inventor/ohad-ilovich-8cqn5jg5

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ohad Ilovich: Innovator in Molecular Imaging

Introduction

Ohad Ilovich is a notable inventor based in Kadima, Israel. He has made significant contributions to the field of molecular imaging, particularly through his innovative work on myocardial perfusion agents.

Latest Patents

Ohad Ilovich holds a patent for molecular imaging agents. This patent involves the use of radiolabeled ammonium salts as myocardial perfusion agents in molecular imaging. His work in this area has the potential to enhance diagnostic capabilities in medical imaging.

Career Highlights

Ohad Ilovich is associated with Hadasit Medical Research Services and Development Ltd., where he continues to advance research in medical technologies. His expertise in molecular imaging has positioned him as a key figure in this specialized field.

Collaborations

Ohad has collaborated with notable colleagues, including Eyal Yosef Mishani and Hana Billauer. These partnerships have contributed to the development of innovative solutions in medical research.

Conclusion

Ohad Ilovich's contributions to molecular imaging exemplify the impact of innovation in healthcare. His work continues to pave the way for advancements in medical diagnostics.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…